OS Therapies’ (OSTX) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of OS Therapies (NYSE:OSTX) in a research report report published on Thursday morning,Benzinga reports. D. Boral Capital currently has a $20.00 price target on the stock.

Separately, Maxim Group lifted their price target on shares of OS Therapies from $8.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday, January 16th.

OS Therapies Stock Performance

NYSE:OSTX opened at $1.84 on Thursday. OS Therapies has a one year low of $1.58 and a one year high of $7.00. The stock has a 50-day simple moving average of $3.42.

Insider Activity

In other news, major shareholder Shalom Auerbach sold 16,720 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $6.74, for a total transaction of $112,692.80. Following the completion of the transaction, the insider now directly owns 2,531,211 shares of the company’s stock, valued at approximately $17,060,362.14. This represents a 0.66 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Institutional Investors Weigh In On OS Therapies

A hedge fund recently bought a new stake in OS Therapies stock. Virtu Financial LLC purchased a new position in shares of OS Therapies Inc (NYSE:OSTX) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 10,045 shares of the company’s stock, valued at approximately $28,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.